 |
PDBsum entry 2xb7
|
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
|
|
PDB id:
|
|
|
|
| Name: |
|
Transferase
|
|
|
Title:
|
|
Structure of human anaplastic lymphoma kinase in complex with nvp- tae684
|
|
Structure:
|
|
Alk tyrosine kinase receptor. Chain: a. Fragment: kinase domain, residues 1094-1407. Synonym: anaplastic lymphoma kinase, cd246. Engineered: yes
|
|
Source:
|
|
Homo sapiens. Human. Organism_taxid: 9606. Expressed in: spodoptera frugiperda. Expression_system_taxid: 7108.
|
|
Resolution:
|
|
|
2.50Å
|
R-factor:
|
0.195
|
R-free:
|
0.243
|
|
|
Authors:
|
|
R.T.Bossi,M.B.Saccardo,E.Ardini,M.Menichincheri,L.Rusconi,P.Magnaghi, P.Orsini,G.Fogliatto,J.A.Bertrand
|
|
Key ref:
|
|
R.T.Bossi
et al.
(2010).
Crystal structures of anaplastic lymphoma kinase in complex with ATP competitive inhibitors.
Biochemistry,
49,
6813-6825.
PubMed id:
|
|
|
Date:
|
|
|
08-Apr-10
|
Release date:
|
28-Jul-10
|
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
|
Headers
|
|
|
|
References
|
|
|
|
|
|
|
|
Q9UM73
(ALK_HUMAN) -
ALK tyrosine kinase receptor from Homo sapiens
|
|
|
|
Seq:
Struc:
|
|
|
|
1620 a.a.
286 a.a.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Key: |
 |
PfamA domain |
|
|
 |
Secondary structure |
|
 |
CATH domain |
|
|
|
|
|
|
|
|
|
|
|
|
|
Enzyme class:
|
|
E.C.2.7.10.1
- receptor protein-tyrosine kinase.
|
|
|
|
|
|
|
Reaction:
|
|
L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + ADP + H+
|
|
|
|
|
|
L-tyrosyl-[protein]
|
+
|
ATP
|
=
|
O-phospho-L-tyrosyl-[protein]
|
+
|
ADP
|
+
|
H(+)
|
|
|
|
|
|
|
|
|
|
|
|
|
Molecule diagrams generated from .mol files obtained from the
KEGG ftp site
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
| |
|
|
| |
|
|
Biochemistry
49:6813-6825
(2010)
|
|
PubMed id:
|
|
|
|
|
|
| |
|
Crystal structures of anaplastic lymphoma kinase in complex with ATP competitive inhibitors.
|
|
R.T.Bossi,
M.B.Saccardo,
E.Ardini,
M.Menichincheri,
L.Rusconi,
P.Magnaghi,
P.Orsini,
N.Avanzi,
A.L.Borgia,
M.Nesi,
T.Bandiera,
G.Fogliatto,
J.A.Bertrand.
|
|
|
|
|
| |
ABSTRACT
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
|
| |
PubMed id
|
|
Reference
|
|
|
|
|
|
E.L.Carpenter,
and
Y.P.Mossé
(2012).
Targeting ALK in neuroblastoma--preclinical and clinical advancements.
|
| |
Nat Rev Clin Oncol,
9,
391-399.
|
|
|
|
|
|
|
K.Kinoshita,
Y.Ono,
T.Emura,
K.Asoh,
N.Furuichi,
T.Ito,
H.Kawada,
S.Tanaka,
K.Morikami,
T.Tsukaguchi,
H.Sakamoto,
T.Tsukuda,
and
N.Oikawa
(2011).
Discovery of novel tetracyclic compounds as anaplastic lymphoma kinase inhibitors.
|
| |
Bioorg Med Chem Lett,
21,
3788-3793.
|
|
|
|
|
|
|
M.Okamoto,
H.Kojima,
N.Saito,
T.Okabe,
Y.Masuda,
T.Furuya,
and
T.Nagano
(2011).
Virtual screening and further development of novel ALK inhibitors.
|
| |
Bioorg Med Chem,
19,
3086-3095.
|
|
|
|
|
|
|
T.Sasaki,
K.Okuda,
W.Zheng,
J.Butrynski,
M.Capelletti,
L.Wang,
N.S.Gray,
K.Wilner,
J.G.Christensen,
G.Demetri,
G.I.Shapiro,
S.J.Rodig,
M.J.Eck,
and
P.A.Jänne
(2010).
The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers.
|
| |
Cancer Res,
70,
10038-10043.
|
|
|
|
|
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
|
|
Links
